These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19366825)

  • 21. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
    Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
    J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
    J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
    de Bono JS; Bellmunt J; Attard G; Droz JP; Miller K; Flechon A; Sternberg C; Parker C; Zugmaier G; Hersberger-Gimenez V; Cockey L; Mason M; Graham J
    J Clin Oncol; 2007 Jan; 25(3):257-62. PubMed ID: 17235043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.
    Montanari M; Fabbri F; Rondini E; Frassineti GL; Mattioli R; Carloni S; Scarpi E; Zoli W; Amadori D; Cruciani G
    Tumori; 2012 Nov; 98(6):696-701. PubMed ID: 23389354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L
    Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
    J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
    Stein MN; Hussain M; Stadler WM; Liu G; Tereshchenko IV; Goodin S; Jeyamohan C; Kaufman HL; Mehnert J; DiPaola RS
    Clin Genitourin Cancer; 2016 Feb; 14(1):22-7. PubMed ID: 26476589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of sunitinib in men with advanced prostate cancer.
    Dror Michaelson M; Regan MM; Oh WK; Kaufman DS; Olivier K; Michaelson SZ; Spicer B; Gurski C; Kantoff PW; Smith MR
    Ann Oncol; 2009 May; 20(5):913-20. PubMed ID: 19403935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
    Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
    Amato RJ; Wilding G; Bubley G; Loewy J; Haluska F; Gross ME
    Clin Genitourin Cancer; 2012 Dec; 10(4):232-8. PubMed ID: 22695254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
    Sonpavde G; Matveev V; Burke JM; Caton JR; Fleming MT; Hutson TE; Galsky MD; Berry WR; Karlov P; Holmlund JT; Wood BA; Brookes M; Leopold L
    Ann Oncol; 2012 Jul; 23(7):1803-8. PubMed ID: 22112969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
    Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
    Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.